Fred Alger Management LLC Acquires New Position in uniQure N.V. $QURE

Fred Alger Management LLC bought a new position in shares of uniQure N.V. (NASDAQ:QURE) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,290,391 shares of the biotechnology company’s stock, valued at approximately $75,320,000. Fred Alger Management LLC owned about 2.07% of uniQure at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of QURE. Avoro Capital Advisors LLC increased its stake in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after purchasing an additional 819,444 shares during the last quarter. Aberdeen Group plc lifted its position in shares of uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after buying an additional 189,029 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of uniQure during the 2nd quarter worth $29,217,000. Franklin Resources Inc. boosted its stake in uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after buying an additional 383,066 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after buying an additional 1,491,486 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on QURE. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $43.25.

uniQure Price Performance

uniQure stock opened at $15.53 on Monday. The stock has a 50-day moving average price of $21.37 and a two-hundred day moving average price of $29.68. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50. The company has a market capitalization of $971.09 million, a PE ratio of -4.50 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. Analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. The trade was a 2.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last quarter. Insiders own 4.79% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.